EMEA-000254-PIP01-08 - paediatric investigation plan

nicotinic acid
simvastatin
laropiprant
PIPHuman

Key facts

Active Substance
  • nicotinic acid
  • simvastatin
  • laropiprant
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/72/2008
PIP number
EMEA-000254-PIP01-08
Pharmaceutical form(s)
Modified-release tablet
Condition(s) / indication(s)
Hypercholesterolaemia
Route(s) of administration
Oral use
Contact for public enquiries

Merck Sharp and Dohme (Europe), Inc.

Belgium
Tel. +33 180464738
E-mail: pip.information@merck.com

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page